ADMA Biologics Q2 Earnings Call Highlights
ADMA Biologics NASDAQ: ADMA reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year financial outlook and said it remains on track to meet or exceed those expectations.
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
In the latest trading session, Adma Biologics (ADMA) closed at $8.48, marking a +2.54% move from the previous day.
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Adma Biologics (ADMA) settling at $8.59, representing a -1.83% change from its previous close.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Adma Biologics (ADMA) settling at $9.16, representing a +2.35% change from its previous close.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) closed at $8.37 in the latest trading session, marking a -4.34% move from the prior day.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Adma Biologics (ADMA) concluded the recent trading session at $8.69, signifying a +1.4% move from its prior day's close.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
